Manuel
Valladares Ayerbes
Hospital Miguel Servet
Zaragoza, EspañaPublications in collaboration with researchers from Hospital Miguel Servet (8)
2024
-
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907
2023
2022
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
ESMO open, Vol. 6, Núm. 2, pp. 100062
2018
-
A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer
Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329
-
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial
Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444
2015
-
Current controversies in the management of metastatic colorectal cancer
Cancer Chemotherapy and Pharmacology, Vol. 76, Núm. 4, pp. 659-677